HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Neutral 54.8%

Neg 0% Neu 54.8% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.